#1 Clinical Trials Search in Europe

Daxdilimab

Daxdilimab, also known as HZN-7734, is an investigational drug being studied in clinical trials for various autoimmune conditions. These trials aim to evaluate the efficacy and safety of daxdilimab in treating diseases such as discoid lupus erythematosus, lupus nephritis, and idiopathic inflammatory myositis. The studies involve administering the drug subcutaneously and comparing its effects to a placebo in reducing disease activity and improving patients’ quality of life.

Table of Contents

What is Daxdilimab?

Daxdilimab, also known by its research name HZN-7734, is an investigational drug being studied for the treatment of various autoimmune diseases[1][2][3]. Autoimmune diseases are conditions where the body’s immune system mistakenly attacks healthy cells. Daxdilimab is designed to help regulate the immune system and reduce this harmful activity.

Conditions Treated by Daxdilimab

Daxdilimab is currently being studied for several autoimmune conditions:

  • Discoid Lupus Erythematosus (DLE): A skin condition characterized by red, inflamed patches on the skin that can cause scarring[1].
  • Lupus Nephritis (LN): A type of kidney inflammation caused by systemic lupus erythematosus (SLE)[2].
  • Dermatomyositis (DM): A rare inflammatory disease that causes skin rashes and muscle weakness[3].
  • Anti-synthetase Inflammatory Myositis (ASIM): A type of inflammatory muscle disease associated with specific antibodies[3].

How is Daxdilimab Administered?

Daxdilimab is administered through subcutaneous injections. This means the medication is injected just under the skin[1][2][3]. In the ongoing clinical trials, patients typically receive two injections for each dose. The frequency of dosing varies depending on the specific study, but it’s often given once every four weeks (Q4W)[1].

Current Clinical Trials

Daxdilimab is currently being evaluated in several Phase 2 clinical trials:

  1. Discoid Lupus Erythematosus Study: This trial is testing daxdilimab in patients with moderate-to-severe DLE who haven’t responded well to standard treatments. The study will last about 60 weeks, with 48 weeks of treatment[1].
  2. Lupus Nephritis Study: This trial is investigating daxdilimab in patients with active, proliferative lupus nephritis. The study will last about 116 weeks, with 104 weeks of treatment[2].
  3. Dermatomyositis and Anti-synthetase Inflammatory Myositis Study: This trial is evaluating daxdilimab in patients with inadequately controlled DM or ASIM. The study will last up to 60 weeks[3].

How Efficacy is Measured

The effectiveness of daxdilimab is measured differently for each condition:

  • For DLE, researchers use the Cutaneous Lupus Erythematosus Disease and Severity Index-Activity (CLASI-A) score. This measures the severity of skin symptoms[1].
  • For Lupus Nephritis, the main measure is the proportion of patients achieving a complete renal response. This indicates significant improvement in kidney function[2].
  • For DM and ASIM, the primary measure is the Total Improvement Score (TIS). This score combines improvements in six different aspects of the disease[3].

Safety Monitoring

As with all clinical trials, the safety of daxdilimab is closely monitored. Researchers are tracking:

  • Treatment-emergent adverse events (TEAEs): Any new medical problems that occur after starting the treatment.
  • Serious adverse events (SAEs): Any severe medical issues that may or may not be related to the treatment.
  • Anti-Drug Antibodies (ADAs): The body’s immune response to the drug itself.
  • Events of Special Interest: Specific health issues that are being closely watched, such as infections or allergic reactions[1][2][3].

It’s important to note that daxdilimab is still an investigational drug. This means it hasn’t been approved by regulatory agencies like the FDA for general use. The ongoing clinical trials will help determine if daxdilimab is safe and effective for treating these autoimmune conditions.

Trial Name Condition Primary Outcome Duration Number of Participants
NCT05591222 Discoid Lupus Erythematosus Change in CLASI-A score from Baseline to Week 24 60 weeks 99
NCT05540665 Lupus Nephritis Complete renal response at Week 48 and sustained through Week 52 116 weeks 210
NCT05669014 Idiopathic Inflammatory Myositis (DM and ASIM) Total Improvement Score (TIS) at Week 24 36-60 weeks Not specified

FAQ

  • What is Daxdilimab? Daxdilimab, also known as HZN-7734, is an investigational drug being studied for the treatment of various autoimmune conditions. It is administered subcutaneously (under the skin) in clinical trials.
  • What conditions is Daxdilimab being studied for? Daxdilimab is being studied for several autoimmune conditions, including discoid lupus erythematosus, lupus nephritis, dermatomyositis, and anti-synthetase inflammatory myositis.
  • How is Daxdilimab administered in clinical trials? In the clinical trials, Daxdilimab is administered subcutaneously (under the skin) as two injections for each dose. The frequency of administration varies depending on the specific trial, but it is often given every four weeks.
  • What are the main goals of the Daxdilimab clinical trials? The main goals of the Daxdilimab clinical trials are to evaluate its efficacy in reducing disease activity, assess its safety and tolerability, and determine its effects on specific symptoms related to each condition being studied.
  • How long do the Daxdilimab clinical trials typically last? The duration of Daxdilimab clinical trials varies, but they generally last between 48 to 116 weeks, including screening periods, treatment periods, and follow-up periods. Some trials may have extension periods for longer-term evaluation.

Ongoing Clinical Trials on Daxdilimab

  • Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

    Not recruiting

    1
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Greece +1

Glossary

  • Discoid Lupus Erythematosus (DLE): A chronic skin condition characterized by red, inflamed disk-shaped patches on the skin, typically on the face, ears, and scalp.
  • Lupus Nephritis (LN): A type of kidney inflammation caused by systemic lupus erythematosus (SLE), which can lead to kidney damage if left untreated.
  • Idiopathic Inflammatory Myositis: A group of rare conditions that cause muscle inflammation (myositis) of unknown origin, leading to muscle weakness and other symptoms.
  • Dermatomyositis (DM): A rare inflammatory disease characterized by muscle weakness and a distinctive skin rash.
  • Anti-synthetase Inflammatory Myositis (ASIM): A subtype of inflammatory myositis associated with the presence of specific antibodies called anti-synthetase antibodies.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Placebo: An inactive substance that looks like the drug being tested, used as a control in clinical trials to determine the effectiveness of the actual drug.
  • Efficacy: The ability of a drug or treatment to produce the desired effect or outcome in treating a condition.
  • Anti-Drug Antibody (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially affect the drug's effectiveness or cause side effects.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.eu/trial/study-on-the-effects-of-daxdilimab-for-adults-with-moderate-to-severe-discoid-lupus-erythematosus/
  2. https://clinicaltrials.gov/study/NCT05540665
  3. https://clinicaltrials.gov/study/NCT05669014